Literature DB >> 6380209

Localization of antileukoprotease in the parotid and the submandibular salivary glands.

M Ohlsson, U Fryksmark, A Polling, H Tegner, K Ohlsson.   

Abstract

Antileukoprotease is the dominating inhibitor of granulocyte elastase and cathepsin G in normal human mixed and parotid saliva. The distribution of antileukoprotease in the submandibular and parotid glands was analysed with an immunoperoxidase technique using specific antibodies against antileukoprotease. Antileukoprotease was demonstrated in the serous cells of both the submandibular and parotid glands. These findings suggest that there is a local production of the inhibitor in the parotid gland and submandibular gland and are in agreement with our previous work which demonstrated high concentrations of the inhibitor in parotid saliva.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380209     DOI: 10.3109/00016488409107547

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

Authors:  S M Wahl; P Worley; W Jin; T B McNeely; S Eisenberg; C Fasching; J M Orenstein; E N Janoff
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

2.  Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.

Authors:  N K Jana; L R Gray; D C Shugars
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Localization of immunoreactive secretory leukocyte protease inhibitor (SLPI) in intestinal mucosa.

Authors:  M Bergenfeldt; M Nyström; M Bohe; C Lindström; A Polling; K Ohlsson
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

4.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.

Authors:  Amit Chattopadhyay; Laurie R Gray; Lauren L Patton; Daniel J Caplan; Gary D Slade; Hsaio-Chuan Tien; Diane C Shugars
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.

Authors:  M Nyström; M Bergenfeldt; I Ljungcrantz; A Lindeheim; K Ohlsson
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

7.  Human mast cells decrease SLPI levels in type II - like alveolar cell model, in vitro.

Authors:  Camilla Hollander; Max Nyström; Sabina Janciauskiene; Ulla Westin
Journal:  Cancer Cell Int       Date:  2003-08-20       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.